ArticleAnnals of hepatology
Telemedicine, COVID-19 and liver diseases: Revamping remote care initiatives in hepatology.
Article in Annals of hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Telemedicine in the tertiary liver unit: A feasibility study.Clinical and experimental hepatology · 2024Article
- Telephone-Only Visits Preserved Hepatocellular Cancer Screening Rates in Patients with Cirrhosis Early in the COVID-19 Pandemic.Digestive diseases and sciences · 2023Article
- The impact of COVID-19 on liver transplantation: challenges and perspectives.Therapeutic advances in gastroenterology · 2023Review
- Modifying UTAUT2 for a cross-country comparison of telemedicine adoption.Computers in human behavior · 2022Article
- Barriers to hepatitis C diagnosis and treatment in the DAA era: Preliminary results of a community-based survey of primary care practitioners.Canadian liver journal · 2022Article
- The Role of Telemedicine in Surgical Specialties During the COVID-19 Pandemic: A Scoping Review.World journal of surgery · 2022Article
- Impact of COVID-19 Response on Hepatitis Prevention Care and Treatment: Results From Global Survey of Providers and Program Managers.Clinical liver disease · 2021Review
- Utilizing Telemedicine and Modified Fibrosis Staging Protocols to Maintain Treatment Initiation and Adherence Among Hepatitis C Patients During the COVID-19 Pandemic.Journal of primary care & community healthArticle
- COVID-19 and the liver: What do we know after six months of the pandemic?Annals of hepatologyArticle
- Viruses and the Liver 2020: Before COVID-19 and the beginning of a new age in medicine.Annals of hepatologyArticle
- Hepatology and the "new reality" ushered in by the COVID-19 pandemic.Annals of hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.